Article
Repurpose of Ritlecitinib Reduces Neointima Formation and Enhances Endothelial Recovery Following Vascular Injury
2025-09-25
Abstract excerpt
<h4>Background</h4> Neointimal hyperplasia after vascular injury reflects excess smooth muscle cell (SMC) proliferation with impaired endothelial recovery. We tested the hypothesis that selective Janus kinase 3 (JAK3) inhibition with the FDA-approved drug Ritlecitinib limits neointima while accelerating reendothelialization. <h4>Methods</h4> We used mouse carotid wire injury and a human internal mammary artery (...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4a45f1b4-eeb1-531a-9d6c-96d1e6e2a87e
- DOI
- 10.1101/2025.09.23.678172
